E Ann Tallant

Title: E Ann Tallant: Innovator in Cancer Therapeutics

Introduction

E Ann Tallant is a notable inventor based in Lewisville, NC (US). She has made significant contributions to the field of cancer therapeutics, particularly through her research on angiotensin peptides. With a total of 2 patents, her work focuses on innovative approaches to inhibit cancer cell growth.

Latest Patents

Tallant's latest patents include the use of angiotensin-(1-7) and angiotensin-(1-7) agonists for the inhibition of cancer cell growth. The invention describes a composition that comprises a pharmaceutically effective amount of an agonist for the angiotensin-(1-7) receptor. This composition aims to inhibit the growth or proliferation of cancer cells. The application of angiotensin-(1-7) or its receptor agonist is associated with an increase in the expression of genes involved in tumor suppression and a decrease in the expression of known oncogenes. The cancers targeted by this invention include those with an angiotensin-(1-7) receptor, such as breast and lung cancer.

Career Highlights

E Ann Tallant is affiliated with Wake Forest University, where she continues her research and development in cancer therapeutics. Her work has garnered attention for its potential impact on cancer treatment and patient outcomes.

Collaborations

Some of her notable coworkers include Patricia Gallagher and Carlos M Ferrario, who have collaborated with her on various research projects.

Conclusion

E Ann Tallant's innovative work in the field of cancer therapeutics highlights her commitment to advancing medical science. Her patents reflect a promising approach to cancer treatment, potentially benefiting many patients in the future.